Three-Color FISH Analysis of TMPRSS2/ERG Fusions in Prostate Cancer Indicates That Genomic Microdeletion of Chromosome 21 Is Associated with Rearrangement  by Yoshimoto, Maisa et al.
Three-Color FISH Analysis of TMPRSS2/ERG Fusions in Prostate
Cancer Indicates That Genomic Microdeletion of Chromosome
21 Is Associated with Rearrangement1
Maisa Yoshimoto*,2, Anthony M. Joshua*,y,z,2, Susan Chilton-MacNeill§, Jane Bayani*, Shamini Selvarajah*,§,
Andrew J. Evans*,b, Maria Zielenska§ and Jeremy A. Squire*,b
*Applied Molecular Oncology, Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Ontario, Canada;
yDepartment of Medical Biophysics, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada;
zDepartment of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada; §Department of
Pathology and Laboratory Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada; bDepartment of
Pathology, Princess Margaret Hospital, Toronto, Ontario, Canada
Abstract
The recent description of novel recurrent gene fusions
inf80% of prostate cancer (PCa) cases has generated
increased interest in the search for new translocations
in other epithelial cancers and emphasizes the impor-
tance of understanding the origins and biologic impli-
cations of these genomic rearrangements. Analysis of
15 PCa cases by reverse transcription–polymerase
chain reaction was used to detect six ERG-related gene
fusion transcripts with TMPRSS2. No TMPRSS2/ETV1
chimeric fusion was detected in this series. Three-color
fluorescence in situ hybridization confirms that
TMPRSS2/ERG fusion may be accompanied by a small
hemizygous sequence deletion on chromosome 21
between ERG and TMPRSS2 genes. Analysis of ge-
nomic architecture in the region of genomic rearrange-
ment suggests that tracts of microhomology could
facilitate TMPRSS2/ERG fusion events.
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Introduction
As the most common neoplasm and second leading cause of
cancer mortality in North American men [1], remarkably little
is known about crucial events in prostatic carcinogenesis.
Two related discoveries over the last 12 months, however,
have the potential to considerably contribute to knowledge in
this area. Initially, Petrovics et al. [2] describedanETS-related
gene (ERG1) in the prostate cancer (PCa) transcriptome,
suggesting that it was the most commonly overexpressed
proto-oncogene in malignant prostatic tissues. Indepen-
dently, Tomlins et al. [3] described novel gene fusions involv-
ing either ERG1 or a related geneETV1 or ETV4 [4], which is
thought to underlie the mechanism of overexpression. These
studies used a novel computational analysis of microarray
data called Cancer Outlier Profile Analysis (COPA) and was
subsequently confirmed by reverse transcription–polymerase
chain reaction (RT-PCR) and fluorescence in situ hybridization
(FISH). A confirmatory study also detected ERG rearrange-
ments but did not detect ETV alteration [5]. The gene fusions
described to date involve the androgen-sensitive TMPRSS2
gene and three aforementioned members of the ETS family of
transcription factors (ERG, ETV1, and ETV4). We provide inde-
pendent confirmation of translocation results in 6 of 15 (40%)
PCa specimens and additionally describe two novel variant tran-
scripts in the same multicentric tumor. In addition, break-apart
three-color FISH was used to confirm that a deletion between
TMPRSS2 and ERG on chromosome 21 was associated with
gene fusion events.
Materials and Methods
Fifteen typical PCa tissue samples were obtained from radical
prostatectomies. Part of the tissue was embedded in frozen
section medium and stored at 80jC until a tumor-rich tissue
had been selected for RNA extraction. FISH analysis was per-
formed on adjacent sections. Tissue sections were also stained
with hematoxylin and eosin and subjected to standard histo-
pathological evaluation to determine pathological grade, tumor
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content, and the presence or absence of single/multifocal
PCa. Gleason scores ranged from 6 to 9, and one tumor
sample (78-01) was considered to have multicentric his-
tology. To determine the prevalence of ETS rearrangement,
RT-PCR amplification (GeneAmp RNA PCR Core Kit; Ap-
plied Biosystems, Foster City, CA) was carried out as de-
scribed by Tomlins et al. [3]. Duplicated RT-PCR products
from 15 PCa cases were sized by electrophoresis on a 1.5%
agarose gel and by DNA 1000 LabChip Kit (Agilent 2100
Bioanalyzer; Agilent Technologies, Inc., Palo Alto, CA).
These products were then gel-purified and sequenced di-
rectly using an ABI PRISM 377 (Applied Biosystems) se-
quencer (Figure 1, B and C).
To confirm the presence of TMPRSS2/ERG fusions, we
used interphase FISH assays on corresponding frozen sec-
tions. A break-apart FISH strategy was employed in the
analysis of ERG gene rearrangement using bacterial arti-
ficial chromosome (BAC) DNA probes published previously
[3]. This approach consisted of two DNA probes positioned
at opposite sides of the breakpoint region of the ERG gene
(ERG 5V and ERG 3V loci) and differential labeling using the
Ulysis Nucleic Acid Labeling kit (Molecular Probes, Eugene,
OR). The OregonGreen-labeled RP11-95I21 BAC probe
spans the ERG 5V and extends inward into exon 10. The
red-fluorescein– labeled RP11-476D17 BAC probe spans
the ERG 3V locus and extends inward past exon 4. There is
a 35-kb gap between the 3V and 5V ERG probes. The
TMPRSS2 gene was identified using the Pacific Blue–
labeled RP11-35C4 BAC probe, which starts 2.7 Mb from
the 5V end of the ERG gene (Figure 2). The FISH criteria used
to evaluate TMPRSS2/ERG rearrangement were as fol-
lows: [1] visualization of separate green 5V ERG and red 3V
ERG signals, and [2] enumeration of each green, red, and
blue signal.
DAPI-stained tumor nuclei (dark blue) were identified in
an adjacent H&E–stained frozen tissue. Normal signal
patterns of the probes were confirmed by the colocalization
of OregonGreen-labeled 5V ERG (green signals), AlexaFluor
594– labeled 3V ERG (red signals), and Pacific Blue–
labeled TMPRSS2 (pale blue signals) in normal peripheral
lymphocyte metaphase cells and in normal interphase cells
(Figure 3A). ERG rearrangement was confirmed by the
split of one of the colocalized signals, in addition to a fused
signal of the unaffected chromosome 21 (Figure 3B). A
minimum of 300 signals per probe was counted to confirm
the TMPRSS2/ERG rearrangement in PCa specimens pre-
viously analyzed by RT-PCR. A decreased ratio for the 5V
ERG probe mapping to the genomic interval between the
Figure 1. Rearrangement of the TMPRSS2 and ERG genes in PCa. (A) RT-
PCR products from six PCa cases were sized using the Agilent 2100
Bioanalyzer. The fragments were analyzed with a ladder marker to determine
the size of each variant TMPRSS2/ERG transcript. Depending on the
breakpoints within each, the fragments were 800, 600, ~430, and ~350 bp.
(B) Sequence electropherograms of mutant TMPRSS2/ERG transcripts from
case 78-01. Two unique variant transcripts were found to be present in this
case: one containing exons 1 and 2 of the TMPRSS2 gene and exons 5 and 6 of
the ERG gene, and the other containing exon 1 of the TMPRSS2 gene joined to
exons 5 and 6 of the ERG gene. The arrows indicate gene breakpoints. (C)
Schematic representation of the exon composition of the TMPRSS2/ERG
gene fusion products from variant PCa cases.
Figure 2. Location and names of the BAC probes and gene locations used in the analysis. Gene locations are taken from the May 2004 assembly of the UCSC
Genome Browser. Numbers indicate basepair location along the chromosome. Colors correspond to fluorochromes used in FISH experiments.
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TMPRSS2 region and 3V ERG (Figure 2) was indicative of
hemizygous deletion. These experiments were optimized
using FISH ratios present in normal adjacent tissues, and
deletion cutoff values were defined as a ratio of green 5VERG
signal to red 3V ERG (V 0.80) [6] when break-apart FISH
analysis indicated that a fusion genomic rearrangement
was present.
Results and Discussion
Of the 15 tumors analyzed, 6 (40%) possessed an ERG
rearrangement, confirming the FISH findings of a previous
study (55%; 16 of 29) [3]. Although none of our samples had
an ETV1 rearrangement, this observation is not surprising
because the original paper only detected the ETV1 fusion
transcript in a smaller proportion of samples (25%; 7 of 29)
and because the confirmatory study by Soller et al. [5] did not
detect ETV1 alteration in 18 tested samples. Using the
Agilent 2100 Bioanalyzer, fragment lengths were precisely
determined. Five of six positive ERG/TMPRSS2 fusions
had lengths consistent with published findings; however,
one tumor sample (PCa 78-01) contained two variant
TMPRSS2/ERG transcripts (Figure 1A, lane 6) of 430 and
350 bp. Automated DNA sequencing of gel-purified tran-
scripts from PCa 66-01 and PCa 79-01 (both typical
TMPRSS2/ERG fusions) and from PCa 78-01 (upper and
lower fragments) confirmed the fusion of TMPRSS2 with the
ERG gene. Sequence analysis of both gel-purified frag-
ments from PCa 78-01 revealed two distinct in-frame re-
arrangements generating novel TMPRSS2/ERG fusion
transcripts. The variant TMPRSS2/ERG transcript of 430 bp
resulted in the fusion of exons 1 and 2 of the TMPRSS2
gene and of exons 5 and 6 of the ERG gene, and the smaller
variant TMPRSS2/ERG transcript of 350 bp resulted in the
fusion of exon 1 of the TMPRSS2 gene to exons 5 and 6 of
the ERG gene (Figure 1C). Although it is conceivable that
these fusion events represent independent genomic altera-
tions occurring within one clonal tumor outgrowth, this inter-
pretation was considered less likely given the multicentric
histology of this particular tumor. The detection of these two
new variant TMPRSS2/ERG fusions brings the total number
of ETS gene fusions in PCa described to date to 11 (Table 1).
Applying the break-apart green (ERG 5V locus) and red
(ERG 3V locus) FISH strategies allowed for the confirmation of
TMPRSS2/ERG fusion in frozen sections from six different
patients. Within these six patient samples, deletion between
TMPRSS2 and ERG was detected in three samples. In all
cases, enumeration with flanking TMPRSS2 (pale blue) and
5V ERG (green) in tumors showed that the ratio was < 0.80,
consistent with deletion affecting the intervening genomic
DNA. Additional preliminary data have confirmed that a
subset of these tumors demonstrated hemizygous deletion
by oligonucleotide array-based comparative genomic hybrid-
ization (aCGH) (Human Genome CGH Microarray Kit 44B;
Agilent Technologies, Inc., Palo Alto, CA) intervening in
TMPRSS2/ERG fusion (data not shown).
Figure 3. FISH analysis showing rearrangement of TMPRSS2 and ERG
genes in PCa. (A) FISH confirms the colocalization of OregonGreen-labeled 5 V
ERG (green signals), AlexaFluor 594– labeled 3 V ERG (red signals), and Pa-
cific Blue– labeled TMPRSS2 (light blue signals) in normal peripheral
lymphocyte metaphase cells and in normal interphase cells. (B) In PCa cells,
break-apart FISH results in a split of the colocalized 5 V green/3 V red signals, in
addition to a fused signal (comprising green, red, and blue signals) of the
unaffected chromosome 21. Using the TMPRSS2/ERG set of probes on PCa
frozen sections, TMPRSS2 (blue signal) remains juxtaposed to ERG 3 V (red
signal; see white arrows), whereas colocalized 5 V ERG signal (green) is lost,
indicating the presence of TMPRSS2/ERG fusion and concomitant deletion
of 5 V ERG region.
Table 1. ETS Fusions Documented in PCa to Date.
Variant Name Exon Breakpoint Source
TMPRSS2 ERG ETV1 ETV4
1a 1 4 [3]
1b 2 4 [3]
A 1 4 [3]
B 1 2 [3]
C 2 5 This study
D 1 5 This study
E 5 4 [5]
F 4 5 [5]
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Genomic Architecture and Origin of Genetic Translocations
Although there are many transcripts recognized, the
human ETV1 gene has up to 14 exons with a DNA binding
domain in the last exon, whereas theERG gene has 11 exons
with recognized functional domains occurring across exons
5 and 6 [pointed (PNT) domain interaction] and exon 11 (ETS
DNA binding domain). TMPRSS2 has 14 exons with func-
tional domains in the latter half of the protein only. Both ERG
and TMPRSS2 lie on chromosome 21 at cytobands 21q22.3
and 21q22.2, respectively, with approximately 3 Mb between
them, and TMPRSS2 localized more telomerically than ERG.
As can be seen in Figure 2, the 5V end of both genes faces the
telomere. Both genes have the same transcriptional orienta-
tion and are separated by 3 Mb of DNA. Given this genomic
organization and the observation that 5V TMPRSS2 fuses
in-frame with 3V ERG, interstitial deletion of the intervening
3 Mb of DNA must take place. Indeed, our three-color FISH
analysis confirms the loss of genomic content from this region
of chromosome 21. This finding raises the question of con-
comitant haploinsufficiency of one or more genes mapping to
this deleted interval. Deletion of the TMPRSS2 coding region
resulting from fusion rearrangement may lead to haplo-
insufficiency of the gene. However, a TMPRSS2 knockout
mouse with no apparent phenotype was recently reported [7].
Examination of the 13 genes within this region of chromo-
some 21 (ETS2, DSCR, BRWD1, HMGN1, C21orf13,
SH3BGR, B3GALT5, PCP4, DSCAM, BACE2, FAM3, MX2,
and MX1) identified one candidate locus HMGN1. Knock-
out models of this gene demonstrated that loss increased
N-cadherin expression [8] (which has been noted in high-
grade PCa) [9] and altered G2/M checkpoint [10]. Interest-
ingly, COPA analysis using the Oncomine database [11] of
PCa (an expression microarray dataset) [12] demonstrated
that, when ERG was overexpressed, there was concomitant
reduction in the expression of HMGN1.
The clarification of the exact genomic architecture will
involve the sequencing or the fiber FISH analysis of samples
that have been found to express the fusion transcript. Similar
rearrangements involving ETS family members in the Ewing
family of tumors and hematologic malignancies have been
shown to involve classic, complex, or variant translocations.
Interstitial deletions have been described in leukemias [13]
and congenital syndromes, and are thought to be due to
defective homologous recombination [14], which is perhaps
related to DNA matrix attachment regions or areas of micro-
homology. In this regard, it is noteworthy that, for every case
of ERG fusion transcript, there is at least one area of up to
300 bp on the intron following the transcribedTMPRSS2 exon
that displays microhomology with up to 90% identity to
multiple areas on the intron preceding the relevant ERG exon
of the transcript.
Functional Implications
The most pressing need in future work is the need to
demonstrate the existence of functional protein from these
transcripts. From the analysis of fusion transcripts, it is evi-
dent that TMPRSS2 contributes an androgen-responsive
regulatory region to ERG, ETV1, and ETV4. Identification of
the contribution of other structural regions, such as the PNT
domain, which is important for TMPRSS2/ERG and
TMPRSS2/ETV1 function, and elucidation of the precise
functional properties of each fusion protein are areas of sig-
nificant future interest. Indeed, the only other study ex-
amining ERG expression in PCa, using an antibody to the
conserved C-terminus, found expression in 7 of 25 of high-
grade cancers [15].
The ETS family of transcription factors encodes nuclear
transcription factors with an evolutionarily conserved ETS
domain of 85 amino acids that mediate binding to purine-rich
DNA residues with more than 400 target genes in the ge-
nome that are either positively or negatively regulated by
them [16]. One of the most interesting findings of the study
by Tomlins et al. [3] is the suggestion that fusion genes only
exist in PCa and not in the precursor lesion, high-grade
prostatic intraepithelial neoplasia (HPIN). This suggests
that a consequence of the expression of these gene prod-
ucts may be the facilitation of the cellular transitions of HPIN
precursors to PCa. There is some evidence that ETS-related
genes are involved in invasiveness and metastases [16], but
these novel transcriptomes are yet to be fully characterized.
Evidence to date suggests that ERG may be involved in
histone methylation [17], inhibition of apoptosis [18], and
transcriptional synergy with Jun/Fos heterodimers [19], and,
when overexpressed, display transforming abilities [20].
However, potentially more relevant insights into their dys-
regulated mechanisms can be gained from examining their
role in the Ewing family of tumors and hematologic neo-
plasms, where similar fusion products are known to occur.
For example, both ERG and ETV1 fusion products have
been shown to downregulate the TGF-b2 receptor [21]—a
potential tumor suppressor in PCa [22].
Clinical Implications
The clinical implications of translocation remain unclear.
Intuitively, a translocation would appear to be detrimental;
however, Petrovics et al. [2] described ERG overexpression
in a subset of 95 PCa patients and noted that high levels were
associated with a variety of different positive prognostic
variables such as longer prostate-specific antigen (PSA)
recurrence-free survival, well and moderately differentiated
stages, lower pathological T stage, and negative surgical
margins. Subsequently, the paper by Tomlins et al. [3] indi-
cated that, in greater than 90% of cases overexpressing
ERG or ETV1, a TMPRSS2 fusion event was detectable.
The possibility that the presence of a gene fusion is a positive
prognostic factor raises the possibility that there may be
multiple pathways toward prostatic carcinogenesis, with
varying malignant potentials. In our small cohort, we did not
notice any particular clinical outcome with samples carrying
the rearrangement, and clinical characteristics were dis-
tributed unremarkably; tumor stages ranged from T2a to
T3b—five tumors were Gleason 7 and one tumor was Glea-
son 9. A future area of interest for future investigation is the
response to androgen deprivation in PCa. The response is
known to be heterogeneous, with the median response
before PSA relapse being approximately 24 months [23].
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The nature of this genomic rearrangement suggests that it
may be fundamental to driving carcinogenesis; thus, further
hypotheses may suggest that those with an ETS gene fusion
have a prolonged response to androgen deprivation than
those without.
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